Novo Nordisk's diabetes drug, Ozempic, receives positive CHMP opinion in the EU for expanded use in T2D and CKD patients.

A study published in The New England Journal of Medicine has demonstrated the potential of semaglutide for alleviating knee ...

With several of these drugs going off patent in the next few years, OneSource is poised to see big growth in the generic ...

In the continuation of our discussion with Chris Sayed, MD, University of North Carolina at Chapel Hill Department of ...

Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.

The unregulated use of hormone therapy among young men, looking to boost testosterone levels and enhance their appearances, ...

A slowdown of the digestive tract (gastroparesis) can be a serious side effect, though. Researchers who analyzed the health records of 16 million people revealed that pancreatitis and bowel ...

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...

Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound ...

A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) ...

Studies suggest that semaglutide reduces heart attack and stroke and may curb addiction and more. Scientists reflect on the future of GLP-1 drugs beyond weight loss.

GLP-1 agonists substantially slowed kidney deterioration and failure, independent of diabetes status. The most extensive and ...